Should we all get a vaccine booster (3rd dose)?
New preprint w @billy_gardner_ , we examine impact of 3rd doses on key topic: transmission.
medrxiv.org/content/10.110…
tl;dr 3rd dose could significantly reduce Rt & stop some surges, but doses should 1st go to unvaccinated if possible
Background
COVID-19 vaccines are fantastic. Better than we could have imagined. mRNA vaccines had efficacy of ~95% for symptomatic disease & even better for severe disease & death. But there's now strong evidence that protection against mild disease & infection is waning a bit.
Here's one study from the UK (there are many others) showing a reduction for Pfizer &Astrazeneca.
doi.org/10.1101/2021.0…
Thankfully, waning of protection against severe disease has been much less. Here's a thread reviewing many studies that show this:

Fig from same paper as above (doi.org/10.1101/2021.0…) shows slight waning but still very high protection.
So why all the talk about the need for vaccine boosters?
Why did Biden say we'd all get vaccine boosters after 6 months? Why did FDA & CDC recommend them for 65+, underlying medical conditions & those in high risk settings (cdc.gov/coronavirus/20…).
A couple reasons.
First, there is plenty of evidence that protection, even against severe disease, has waned more in older and ill individuals. e.g.
doi.org/10.1101/2021.0…
Second, even mild COVID-19 disease may have long-term consequences. #LongCovid, although the frequency & severity of LongCovid cases in vaccinated individuals that get mild infections is still uncertain.
Regardless, this means protection against even mild disease is important.
So why is there pushback against vaccine boosters? Recent article @apoorva_nyc: some MDs aren't as supportive of boosters as broad recent CDC recommendations.
nytimes.com/2021/10/25/hea…
Two big reasons:
1) Global vaccine equity: Many populations, especially in Africa, have received no vaccines, so boosting protection a little in rich countries, while millions have no protection is morally wrong.
2) Recommending boosters could reduce confidence in vaccines.
I'm a strong supporter of vaccine equity & COVAX (who.int/initiatives/ac…) & I'd bet almost 100% of epidemiologists (including me) would prefer to give doses to unvaccinated before giving boosters.
However, if sufficient doses were available, a very important question is: what would the impact of boosters be on transmission of SARS-CoV-2? Could boosters reduce transmission enough to prevent a winter surge? That's the Q our paper addresses.
To do so, we had to estimate vaccine protection against against all infections & transmission with waning & boosting. The data to do so directly don't yet exist.
However, early paper showed antibody titers predict protection v disease.
doi.org/10.1038/s41591…
We extended this work by gathering many additional studies on protection against both symptomatic infection & all (but not "any") infections for both Delta & non-Delta variants. Each point is a vaccine-variant study & filled symbols aggregate data for a vaccine-variant.
The relationship b/w protection against infection & neutralizing antibody levels (relative to convalescent sera) was strong, although data for Delta were limited to a few vaccines studied in rich countries (Pfizer, Astrazeneca). Protection was higher vs disease than infection.
We used relationship for protection against all infections for Delta (red line) + very limited study of minimum protection against transmission given infection (doi.org/10.1101/2021.0…) to estimate impacts of boosting on transmission via the pathogen reproductive number, Rt.
We considered 5 several scenarios that varied vaccine coverage, fraction previously infected, & contact rates (which scale R0 & Rt) which roughly describe, using mid-October data: USA, CA, New Zealand w/ summer surge 2021 (R0=~3.7) or pre-pandemic contact rates (R0=~7).
To take into account past vaccinations & infections, we had to estimate waning of protection based on patterns of waning of antibody levels for Pfizer, Moderna, previous infection & hybrid immunity & time series of infections & vaccinations by vaccine type.
We find:
Boosting could substantially reduce Rt, 21%-66%, with larger impacts for higher vaccine coverage & contact rates & smaller fraction previously infected.
Specifically
1)red line: boosting all US currently vaccinated could stop winter surge but only w/ lower contact rates
2) If contact rates return to pre-pandemic levels, need very high vaccine coverage (100%) & 25% boosted to prevent surge (yellow line). w/ current US vaccine coverage (56%) & estimated previous infection (56.4%) Rt remains far above one even if we boost everyone (green line).
3) Places like Calif. (blue line), possibly UK (couldn't find good data on fraction previously infected - help!), could prevent surge w/ some boosting. Australia & New Zealand at risk of very high Rt b/c almost no protection from previous infection. Need to vaccinate fast!
Finally, as expected, using 3rd doses to vaccinate unvaccinated is much more effective. Black dot shows Rt if all 3rd doses used at right end of green line were instead given to unvaccinated (2 shots each) to push coverage 56->84%. Much better, if it could be done.
Conclusions
-3rd dose substantially increases VE vs infection & transmission
-3rd doses could substantially reduce transmission & stop winter surge, but not w/ pre-pandemic behavior unless vacc coverage or prev infection high (~100%)
-doses (always) best used for unvaccinated
Many caveats
Indirect measure of protection (no T-cells!)
Limited data esp. for transmission
No age-specific analysis
V. simple model: assume well-mixed pop for Rt
Didn't incorporate uncertainty in waning for Rt CIs (yet)
Late addition (not yet in paper):
We can use relationship in paper to estimate (HUGE) benefit of getting vaccinated if you've been previously infected:
Protection vs infection increases from 62% -> 91%
Reduced chance of transmitting if infected:
12.5% ->76%
Get vaccinated!!!
Add. caveat: @michaelmina_lab has noted that a sharp increase in antibodies following vaccination often wanes quickly. Unfortunately, we currently don't know how long boosting will last. Have I missed a study from Israel or elsewhere? @florian_krammer @profshanecrotty @roby_bhatt

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with A Marm Kilpatrick

A Marm Kilpatrick Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DiseaseEcology

10 Sep
What is driving current peaks in SARS-CoV-2 cases & what does this mean for the fall & winter?
Although a peak might seem to indicate that we're headed for fewer cases until a new variant arises, unfortunately that's not the case & a surge is both likely & avoidable.
A thread.
One possibility is in nice thread @trvrb suggesting US Delta surge is peaking now b/c 5% more of US pop infected, driving Rt down to 1 (which occurs at peak).
However, as @trvrb notes in addendum (), Rt at peak is 1 b/c of combination of behavior (which drives R0) and fraction susceptible (Rt = R0*S/N).
Read 16 tweets
15 Jun
Nice thread @EdMHill describing modeling from 1 of 3 teams on possible outcomes in UK that guided recent decision to postpone re-opening.
Big takeaways:
-I wish US gov had been open to scientific guidance in 2020
-Big uncertainty in behavior changes w/ re-opening
cont.
-Big uncertainty in relative transmissibility of delta (b.1.617.2) variant & vaccine effectiveness for transmission (not symptomatic disease). PHE-UK has provided fantastic real-time analyses of available data, but some critical data, that could be collected, are missing.
-Importance of limited vaccine supply. US can't seem to give away vaccine even with beer, lotteries & more. In UK (& most, but not all, of world) every dose is precious & in-demand.
Read 4 tweets
26 May
Why hasn't B.1.1.7 fully displaced other variants in US? What other variants are persisting/growing?
Thread
B.1.1.7 has risen to relatively high frequencies in many states, but hasn't exceeded 90% in any of them & may be falling in several.
Data here from @my_helix
GISAID sequences via fantastic outbreak.info for US as a whole suggest B.1.1.7 now stable @70%, P.1 is growing, B.1.526 frequencies are stable. But variable sequencing means finer resolution is better for understanding frequency dynamics, spatial variability & nuance.
Statewide scale is still too large but better than whole US.
Here's FL. Similar pattern as whole US - P.1 growing & B.1.526 stable, leading to slight recent decrease in B.1.1.7
Read 9 tweets
26 May
Yesterday I posted the tweet below as a joke.
Today I found so much bullshit (@callin_bull) it blows my mind.
Exhibit 1: The press release itself: investors.modernatx.com/news-releases/…
Yup, they claim 0 vs 4 cases = 100% efficacy.
Exhibit 2: NBC, USA today both parrot 100% efficacy claim.
Exhibit 3: Moderna CEO claims vaccine prevents infection (see quote). Note: there was no data presented from study on efficacy against infection (despite that being #1 reason to vaccinate kids). Only symptomatic disease (4 cases total), antibody response, & side effects.
It's worth noting that efficacy wasn't a primary endpoint of this trial - translation: the study wasn't trying to measure efficacy so there's no need for Moderna CEO to spout bullshit. Where is NIH partner telling them to cut the BS?
Read 7 tweets
22 May
What is the trajectory of viral load dynamics & test sensitivity post-INFECTION?

We're 17 month into the pandemic &, shockingly, this Q is still only partly answered.
Recent paper using a study design I proposed 12 months ago provides detailed look & raises many questions.
Background
We know that ~3-6d following infection COVID-19 symptoms start (the incubation period). doi:10.1136/
bmjopen-2020-039652
We also know that people are infectious before symptom onset - this has been one of the greatest challenges in controlling SARS-CoV-2.
Read 25 tweets
21 May
How effective are vaccines vs severe & all disease, death, infection, & transmission?
Very nice collection of studies assessing different aspects of vaccine protection by Julia Shapiro (on twitter?) @nataliexdean @betzhallo @ilongini & 2 others.
Thread
medrxiv.org/content/10.110…
Study has data on many different measures of protection:
all infection (symp + asymp), all symptomatic (mild+severe), severe, hospitalization, death, & transmission,
for 8 vaccines: Moderna, Pfizer, Novavax, Astrazeneca, Sinopharm, Sinovac, Sputnik, J&J,
3 variants&
1&2 doses
For those wanting to understand relationships among different vaccine efficacy measures more, recent preprint @mlipsitch @kahnrebecca, lays it out nicely. doi.org/10.1101/2021.0…;
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(